Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from CardieX ( (AU:CDX) ).
Cardiex has successfully completed an institutional placement, raising $2.4 million by issuing over 60 million fully paid ordinary shares to institutional and sophisticated investors at $0.04 per share. The funds will be used for manufacturing, marketing, sales activities, and commercial expansion related to the CONNEQT Pulse device, enhancing Cardiex’s operational capacity and market positioning.
More about CardieX
Cardiex is a company focused on advancing medical technology for vascular health, offering products such as medical and home health devices, and digital solutions targeting hypertension, cardiovascular disease, and other vascular health disorders. Their technology is based on the SphygmoCor® vascular biomarker technology, and they are listed on the Australian Stock Exchange under the ticker ASX:CDX.
Average Trading Volume: 247,420
Technical Sentiment Signal: Sell
Current Market Cap: A$17.87M
For a thorough assessment of CDX stock, go to TipRanks’ Stock Analysis page.